临床荟萃 ›› 2024, Vol. 39 ›› Issue (6): 542-547.doi: 10.3969/j.issn.1004-583X.2024.06.010

• 论著 • 上一篇    下一篇

抗GAD65抗体阳性相关性小脑性共济失调1例及文献回顾

张丽1, 付庆喜2a, 苏明钊2b, 苏全平2b()   

  1. 1.锦州医科大学临沂市人民医院 研究生培养基地, 辽宁 锦州 121000
    2.临市人民医院 a.癫痫睡眠科;b.中心实验室,山东 临沂 276000
  • 收稿日期:2024-02-26 出版日期:2024-06-20 发布日期:2024-07-18
  • 通讯作者: 苏全平,Email: suquanping@163.com
  • 基金资助:
    临沂市重点研发计划——癫痫患者血清细胞因子检测及临床意义(2022YX0011);徐州医科大学附属医院发展基金资助项目——NOX介导TOR信号通路在癫痫中的作用机制研究(XYFM202225);山东第二医科大学附属医院科技发展项目——免疫相关癫痫数据库建立及癫痫患者血清IL-17临床意义研究(2023FYM025);临沂市重点研发计划——基于医疗大数据构建临沂地区成人癫痫持续状态预后模型(2023YX0041)

Cerebellar ataxia associated with antibodies against GAD65: A case report and literature review

Zhang Li1, Fu Qingxi2a, Su Mingzhao2b, Su Quanping2b()   

  1. 1. Postgraduate Training Base, Linyi People's Hospital, Jinzhou Medical University, Jinzhou 121000, China
    2a. Department of Epilepsy and Sleep; b.Central Laboratory, Linyi People's Hospital, Linyi 276000, China
  • Received:2024-02-26 Online:2024-06-20 Published:2024-07-18
  • Contact: Su Quanping, Email:suquanping@163.com

摘要:

目的 探讨抗GAD65抗体阳性相关性小脑性共济失调的临床特征、诊疗要点及预后。方法 分析1例抗GAD65抗体阳性相关性小脑性共济失调患者的临床资料,以“GAD65抗体”和“小脑性共济失调”的中英文为检索词分别在PubMed、CNKI、万方数据知识服务平台和维普中文科技期刊数据库检索国内外相关病例,检索时间至2023年12月,总结抗GAD65抗体阳性相关性小脑性共济失调的临床特点、治疗方案及预后。结果 该病例为67岁男性,缓慢起病,逐渐加重,双下肢无力,不能独立行走。查体:构音欠清,双下肢肌力5-级,双下肢腱反射减退,双侧肢体共济失调,不能直线行走,闭目难立征阳性,双侧病理征阳性。颅脑磁共振平扫显示脑萎缩;血清自身免疫性小脑共济失调14项示抗GAD65抗体IgG 1∶30(阳性)。经过激素冲击及口服免疫制剂治疗,肢体无力症状好转,红细胞计数和血红蛋白含量升高,促甲状腺激素水平降低,甲状腺过氧化物酶抗体水平未有变化。检索到病例报告15篇,论著6篇,涉及到抗GAD65抗体阳性相关性小脑性共济失调的患者186例,该病为慢性进展性发展,临床表现以步态共济失调最常见,可累及脑干,可合并其他自身免疫性疾病,很少合并肿瘤,免疫治疗能改善症状,尽早治疗可使患者受益。结论 抗GAD65抗体阳性相关性小脑性共济失调是自身免疫性小脑共济失调的类型之一,较为罕见,脑脊液或血清GAD65抗体阳性是明确诊断的重要指标,目前治疗方案尚未明确统一,免疫治疗能改善症状。

关键词: 小脑共济失调, 谷氨酸脱羧酶65, 抗体

Abstract:

Objective To investigate the clinical characteristics, diagnosis, treatment and prognosis of cerebellar ataxia associated with antibodies against glutamic acid decarboxylase 65 (GAD65). Methods Clinical data of a case of cerebellar ataxia associated with antibodies against GAD65 were analyzed. Clinical characteristics, diagnosis, treatment and prognosis of cerebellar ataxia associated with antibodies against GAD65 were summarized by searching clinical cases at home and abroad reported before December 2023 in online databases of Pubmed, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service platform and Chinese Science and Technology Periodical Database (VIP) using the key words of “GAD65 antibody” and “cerebellar ataxia”. Results A 67-year-old male presented with weakness in both lower limbs slowly and gradually worsened, and finally he was unable to independently walk. Physical examination showed unclear articulation, level 5 muscle strength of both lower limbs, decreased tendon reflexes in lower limbs, bilateral limb ataxia, unable to walk in a straight line, positive Romberg signs, and positive Babiniski signs. Brain magnetic resonance imaging (MRI) suggested brain atrophy. A panel of 14 diagnostic serum markers of autoimmune cerebellar ataxia showed a weak positivity for GAD65 antibody (IgG 1:30). After hormonal shock therapy and oral immunotherapy, the patient presented an improved symptom of limb weakness, increased red cell count and hemoglobin, and decreased thyroid hormone. Thyroid peroxidase antibody was not significantly changed. Through literature review, 15 case reports and 6 articles reported 186 patients with cerebellar ataxia associated with antibodies against GAD65. The disease develops slowly and progressively. Gait ataxia is the typical clinical manifestation. Cerebellar ataxia associated with antibodies against GAD65 involves the brain stem, and may accompany other autoimmune diseases, but occasionally combines with tumors. Immune therapy is able to alleviate symptoms, and an early treatment provides more clinical benefits. Conclusion Cerebellar ataxia associated with antibodies against GAD65 is a rare type of cerebellar ataxia. Positive detection of GAD65 antibodies in cerebrospinal fluid (CSF) or serum is important for the diagnosis. At present, clinical treatment of cerebellar ataxia associated with antibodies against GAD65 has not yet reached a unified understanding, and immunotherapy can improve clinical symptoms.

Key words: cerebellar ataxia, GAD65, antibody

中图分类号: